Roche (SWX: ROG) has secured a positive CHMP recommendation for Susvimo (ranibizumab injection) 100 mg/mL for neovascular age-related macular degeneration (nAMD), positioning it as the first treatment for the condition in the EU that delivers continuous ocular therapy rather than requiring repeated intravitreal injections. The opinion sets up a European Commission marketing authorization decision that, if granted, would offer the approximately 1.7 million EU patients living with nAMD an alternative to the monthly or near-monthly injection schedules that define current standard of care.
Anti-VEGF injections — including conventional ranibizumab, aflibercept, and brolucizumab — have transformed nAMD outcomes over the past two decades but impose a substantial treatment burden: patients typically require 8 to 12 clinic visits per year, each involving an intravitreal injection under sterile conditions. Susvimo, delivered via the Contivue refillable implant that received CE mark in September 2025, is designed to reduce that to as few as two refill procedures annually while maintaining equivalent visual outcomes.
Susvimo is a customized formulation of ranibizumab distinct from the conventional intravitreal injection marketed as Lucentis (ranibizumab injection), which already holds EU approval for nAMD and other retinal diseases. The Contivue implant — a refillable reservoir surgically inserted into the eye in a one-time outpatient procedure — releases Susvimo continuously into the vitreous. Ranibizumab binds to and inhibits VEGF-A, a protein that drives the formation of abnormal, leaky blood vessels beneath the macula that characterize neovascular AMD. By maintaining a sustained intraocular drug concentration rather than relying on periodic bolus injections, the system aims to provide more consistent VEGF suppression with fewer interventions.
The Contivue platform also includes four ancillary devices for the initial fill, insertion, refill, and, if required, removal of the implant. Roche has indicated it is evaluating other pipeline molecules for potential use with the same Port Delivery Platform, suggesting the Contivue system is intended as a durable delivery infrastructure rather than a single-product vehicle.